Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 202 ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

“Access to the PSPP program will advance our understanding and development of ART26.12,” commented Saoirse O’Sullivan, PhD, Vice President Translational Science at Artelo Biosciences. “We are most ...

THE RISING global prevalence of youth-onset Type 2 diabetes (Y-T2D) is a serious public health concern. With an aggressive ...

If this was going to be what chemo was, I was going to be fine, I thought. Until I wasn’t.